New York State Common Retirement Fund Has $4.78 Million Holdings in Xenon Pharmaceuticals Inc. (NASDAQ:XENE)

New York State Common Retirement Fund raised its holdings in shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) by 7.4% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 142,372 shares of the biopharmaceutical company's stock after purchasing an additional 9,851 shares during the period. New York State Common Retirement Fund owned 0.19% of Xenon Pharmaceuticals worth $4,777,000 at the end of the most recent quarter.

A number of other large investors have also made changes to their positions in XENE. FMR LLC increased its position in shares of Xenon Pharmaceuticals by 8.8% during the fourth quarter. FMR LLC now owns 7,525,290 shares of the biopharmaceutical company's stock worth $294,991,000 after purchasing an additional 607,606 shares in the last quarter. Boxer Capital Management LLC acquired a new position in shares of Xenon Pharmaceuticals in the 4th quarter valued at $23,520,000. JPMorgan Chase & Co. increased its position in shares of Xenon Pharmaceuticals by 38.9% in the 4th quarter. JPMorgan Chase & Co. now owns 1,356,895 shares of the biopharmaceutical company's stock valued at $53,190,000 after acquiring an additional 380,112 shares during the period. Stempoint Capital LP acquired a new position in shares of Xenon Pharmaceuticals in the 4th quarter valued at $14,733,000. Finally, Janus Henderson Group PLC increased its position in shares of Xenon Pharmaceuticals by 12.3% in the 4th quarter. Janus Henderson Group PLC now owns 2,866,755 shares of the biopharmaceutical company's stock valued at $112,425,000 after acquiring an additional 314,363 shares during the period. 95.45% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on XENE shares. Chardan Capital reissued a "buy" rating and issued a $55.00 target price on shares of Xenon Pharmaceuticals in a research report on Tuesday, May 13th. Wells Fargo & Company cut their price target on Xenon Pharmaceuticals from $50.00 to $47.00 and set an "overweight" rating on the stock in a research report on Tuesday, May 13th. HC Wainwright reaffirmed a "buy" rating and set a $53.00 price target on shares of Xenon Pharmaceuticals in a research report on Tuesday, May 13th. Wall Street Zen downgraded Xenon Pharmaceuticals from a "hold" rating to a "sell" rating in a research report on Wednesday, May 21st. Finally, Needham & Company LLC cut their price target on Xenon Pharmaceuticals from $60.00 to $55.00 and set a "buy" rating on the stock in a research report on Tuesday, May 13th. One investment analyst has rated the stock with a sell rating and twelve have assigned a buy rating to the company's stock. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus target price of $54.82.

Xenon Pharmaceuticals Price Performance

NASDAQ:XENE traded down $0.71 during trading hours on Friday, reaching $30.30. 969,939 shares of the company were exchanged, compared to its average volume of 1,432,216. The firm has a market cap of $2.32 billion, a price-to-earnings ratio of -9.38 and a beta of 1.10. Xenon Pharmaceuticals Inc. has a 52-week low of $26.74 and a 52-week high of $46.00. The stock has a 50 day simple moving average of $31.50 and a 200 day simple moving average of $34.64.

Xenon Pharmaceuticals (NASDAQ:XENE - Get Free Report) last released its quarterly earnings results on Monday, May 12th. The biopharmaceutical company reported ($0.83) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.90) by $0.07. The firm had revenue of $7.50 million for the quarter, compared to analysts' expectations of $1.64 million. During the same period last year, the firm earned ($0.62) EPS. On average, analysts predict that Xenon Pharmaceuticals Inc. will post -3.1 EPS for the current fiscal year.

Xenon Pharmaceuticals Company Profile

Xenon Pharmaceuticals Inc, a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders.